Ernexa Therapeutics (ERNA) shares were down 9% in premarket activity on Friday, a day after the company effected a reverse 1-for-15 stock split.
The biotech company's shares began trading on a split-adjusted basis on Thursday.
The company stated that it implemented the split to regain compliance with the $1.00 minimum bid price required for continued listing on Nasdaq.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.